Results for gemini translation from Slovak to English

gemini
gemini

gemini iii štúdia
gemini iii study

zodiac symbol for gemini
bull

výsledky účinnosti pre štúdiu gemini ii v 52. týždni
efficacy results for gemini ii at week 52

u približne polovice pacientov v gemini ii zlyhala predošlá liečba antagonistom tnfα.
in gemini ii, approximately half of patients had previously failed tnfα antagonist therapy.

výsledky účinnosti pre štúdie gemini ii a iii v 6. týždni a 10. týždni
efficacy results for gemini ii and iii studies at week 6 and week 10

lídrami na európskom trhu sú accenture, atos, cap gemini, hp, ibm, wipro atď.
the leaders on the european market include accenture, atos, cap gemini, hp, ibm and wipro.

5 rôznych pripomienok: 1. broadway tours; 2. gemini travel; 3.
5 separate position papers: 1) broadway tours; 2) gemini travel; 3)de vere travel group; 4) adaptable travel; 5) gower tours ltd

prípad iv/m.272 – matra/cap gemini sogeti zo 17. marca 1993.
case iv/m.272 - matra/cap gemini sogeti, of 17 march 1993.

v dôsledku toho bolo v decembri 2009 zrušené osvedčenie aoc dopravcu air gemini a vo februári 2010 bolo zrušené aoc dopravcov pha a sal.
consequently, the aoc of air gemini was revoked in december 2009 and that the aoc of pha and sal were revoked in february 2010.

pacienti, u ktorých sa neprejavila odpoveď v 6. týždni v gemini ii, boli ponechaní v štúdii a dostávali vedolizumab každé štyri týždne.
patients who failed to demonstrate response at week 6 in gemini ii were retained in the study and received vedolizumab every four weeks.

vypracovaním komplexnej štúdie nákladov a prínosov migrácie sepa bola poverená spoločnosť cap gemini consulting a jej výsledky sa uverejnili v januári 2008.
a comprehensive study of the costs and benefits of sepa migration was commissioned from cap gemini consulting and its results published in january 2008.

v kontrolovaných štúdiách gemini i a ii bola miera infekcií 0,85 na pacienta na rok u pacientov liečených vedolizumabom a 0,70 na pacienta na rok u pacientov, ktorým bolo podávanéplacebo.
in gemini i and ii controlled studies, the rate of infections was 0.85 per patient-year in the vedolizumab-treated patients and 0.70 per patient-year in the placebo-treated patients.

pacientom, u ktorých došlo k strate odpovede na vedolizumab, keď boli liečení každých osem týždňov v gemini ii, bolo umožnené vstúpiť do otvorenej predĺženej štúdie a dostávať vedolizumab každé štyri týždne.
patients who lost response to vedolizumab when treated every eight weeks in gemini ii were allowed to enter an open-label extension study and received vedolizumab every four weeks.

frekvencia detekcie protilátok proti vedolizumabu u pacientov 16 týždňov po poslednej dávke vedolizumabu (približne päť polčasov po poslednej dávke) bola približne 10 % v gemini i a ii.
the frequency of anti-vedolizumab antibody detected in patients 16 weeks after the last dose of vedolizumab (approximately five half-lives after the last dose) was approximately 10% in gemini i and ii.

vedolizumab sa skúmal v troch placebom kontrolovaných klinických štúdiáchch u pacientov s ulceróznou kolitídou (gemini i) alebo crohnovou chorobou (gemini ii a iii).
vedolizumab has been studied in three placebo-controlled clinical trials in patients with ulcerative colitis (gemini i) or crohn’s disease (gemini ii and iii).

ide o spoločnosti, ktoré pôsobia v sektore údržby, ako bba group plc, goodrich corp, singapore technologies engineering, hong kong aircraft engineering, služieb v oblasti pozemnej asistencie, ako fraport ag, informatických a zdieľaných služieb ako electronic data systems corp, computer sciences corp, cap gemini sa, indras sistemas sa, atos origin, tietoenator oyj.
these are firms operating in the maintenance field, like bba group plc, goodrich corp, singapore technologies engineering, hong kong aircraft engineering; in groundhandling services, such as fraport ag; and in information technology and shared services, such as electronic data systems corp, computer sciences corp, cap gemini sa, indras sistemas sa, atos origin, tietoenator oyj.